Literature DB >> 23019204

Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly.

Ohad Benjamini, Preetesh Jain, Zeev Estrov, Hagop M Kantarjian, Srdan Verstovsek.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23019204      PMCID： PMC4081400          DOI： 10.1182/blood-2012-07-446849

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  3 in total

1.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

2.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

3.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Authors:  Srdan Verstovsek; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Tapan Kadia; Sherry Pierce; Elias Jabbour; Gautham Borthakur; Elisa Rumi; Ester Pungolino; Enrica Morra; Domenica Caramazza; Mario Cazzola; Francesco Passamonti
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113
  3 in total
  12 in total

1.  An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.

Authors:  Michael R Savona; Luca Malcovati; Rami Komrokji; Ramon V Tiu; Tariq I Mughal; Attilio Orazi; Jean-Jacques Kiladjian; Eric Padron; Eric Solary; Raoul Tibes; Raphael Itzykson; Mario Cazzola; Ruben Mesa; Jaroslaw Maciejewski; Pierre Fenaux; Guillermo Garcia-Manero; Aaron Gerds; Guillermo Sanz; Charlotte M Niemeyer; Francisco Cervantes; Ulrich Germing; Nicholas C P Cross; Alan F List
Journal:  Blood       Date:  2015-01-26       Impact factor: 22.113

2.  Tips on using ruxolitinib in everyday practice as therapy for myelofibrosis.

Authors:  Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2013-08-05

Review 3.  Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.

Authors:  Cecilia Arana Yi; Constantine S Tam; Srdan Verstovsek
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

4.  Ruxolitinib for myelofibrosis: from 'palliation' to prolongation of survival.

Authors:  Srdan Verstovsek
Journal:  Oncology (Williston Park)       Date:  2013-07       Impact factor: 2.990

5.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

Review 6.  Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.

Authors:  A Yacoub; O Odenike; S Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

Review 7.  Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.

Authors:  Jeffrey C Bryan; Srdan Verstovsek
Journal:  Cancer Chemother Pharmacol       Date:  2016-03-26       Impact factor: 3.333

Review 8.  Practical management of patients with myelofibrosis receiving ruxolitinib.

Authors:  Claire Harrison; Ruben Mesa; David Ross; Adam Mead; Clodagh Keohane; Jason Gotlib; Srdan Verstovsek
Journal:  Expert Rev Hematol       Date:  2013-10-02       Impact factor: 2.929

9.  Real-World Assessment of Clinical Outcomes in Patients with Lower-Risk Myelofibrosis Receiving Treatment with Ruxolitinib.

Authors:  Keith L Davis; Isabelle Côté; James A Kaye; Estella Mendelson; Haitao Gao; Julian Perez Ronco
Journal:  Adv Hematol       Date:  2015-11-09

10.  Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis.

Authors:  S Verstovsek; E Atallah; J Mascarenhas; H Sun; M Montgomery; V Gupta; R Mesa; J Gotlib
Journal:  Leukemia       Date:  2015-11-03       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.